TriSalus Life Sciences, Inc.
TLSI
$5.22
-$0.31-5.61%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 26.89M | 24.74M | 21.98M | 18.51M | 16.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.89M | 24.74M | 21.98M | 18.51M | 16.02M |
| Cost of Revenue | 3.47M | 3.05M | 2.91M | 2.61M | 2.84M |
| Gross Profit | 23.42M | 21.68M | 19.07M | 15.91M | 13.18M |
| SG&A Expenses | 46.34M | 46.61M | 45.03M | 40.52M | 32.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 72.19M | 77.33M | 77.84M | 72.80M | 63.63M |
| Operating Income | -45.30M | -52.59M | -55.85M | -54.29M | -47.62M |
| Income Before Tax | -55.45M | -54.47M | -64.11M | -59.17M | -46.20M |
| Income Tax Expenses | 8.00K | 11.00K | 17.00K | 9.00K | 14.00K |
| Earnings from Continuing Operations | -55.46 | -54.49 | -64.13 | -59.18 | -46.21 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.46M | -54.49M | -64.13M | -59.18M | -46.21M |
| EBIT | -45.30M | -52.59M | -55.85M | -54.29M | -47.62M |
| EBITDA | -44.55M | -51.85M | -55.16M | -53.60M | -47.03M |
| EPS Basic | -2.50 | -2.52 | -38.15 | -38.12 | -111.48 |
| Normalized Basic EPS | -1.60 | -2.34 | -22.29 | -22.40 | -63.18 |
| EPS Diluted | -2.50 | -2.52 | -38.15 | -38.12 | -111.48 |
| Normalized Diluted EPS | -1.60 | -2.34 | -22.29 | -22.40 | -63.18 |
| Average Basic Shares Outstanding | 96.96M | 83.63M | 60.17M | 53.02M | 30.12M |
| Average Diluted Shares Outstanding | 96.96M | 83.63M | 60.17M | 53.02M | 30.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
